Jeito Capital leads $67.5 million (€64.4 million[1]) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
January 07, 2025 07:46 ET
|
Jeito Capital
Jeito Capital leads $67.5 million (€64.4 million1) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease Proceeds of financing will support two...
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
January 07, 2025 07:09 ET
|
Jeito Capital
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials ...